Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes

BACKGROUND: The authors evaluated mocetinostat (a class I/IV histone deacetylase inhibitor) in patients with urothelial carcinoma harboring inactivating mutations or deletions in CREB binding protein [CREBBP] and/or E1A binding protein p300 [EP300] histone acetyltransferase genes in a single‐arm, op...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Grivas, Petros, Mortazavi, Amir, Picus, Joel, Hahn, Noah M., Milowsky, Matthew I., Hart, Lowell L., Alva, Ajjai, Bellmunt, Joaquim, Pal, Sumanta K., Bambury, Richard M., O’Donnell, Peter H., Gupta, Sumati, Guancial, Elizabeth A., Sonpavde, Guru P., Faltaos, Demiana, Potvin, Diane, Christensen, James G., Chao, Richard C., Rosenberg, Jonathan E.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6590473/
https://ncbi.nlm.nih.gov/pubmed/30570744
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31817
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados